These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33429859)

  • 1. Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity.
    Lahelma M; Luukkonen PK; Qadri S; Ahlholm N; Lallukka-Brück S; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; Arola J; Orho-Melander M; Yki-Järvinen H
    Nutrients; 2021 Jan; 13(1):. PubMed ID: 33429859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients.
    Li C; Guo P; Okekunle AP; Ji X; Huang M; Qi J; Jiang Y; Feng R; Li R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):256-262. PubMed ID: 29949199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty liver disease and lifestyle in youngsters: diet, food intake frequency, exercise, sleep shortage and fashion.
    Trovato FM; Martines GF; Brischetto D; Catalano D; Musumeci G; Trovato GM
    Liver Int; 2016 Mar; 36(3):427-33. PubMed ID: 26346413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
    Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
    J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study.
    Kwak JH; Jun DW; Lee SM; Cho YK; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC
    Clin Nutr; 2018 Oct; 37(5):1550-1557. PubMed ID: 28918170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HAALT Non-invasive Scoring System for NAFLD in Obesity.
    Sheth H; Bagasrawala S; Shah M; Ansari R; Olithselvan A; Lakdawala M
    Obes Surg; 2019 Aug; 29(8):2562-2570. PubMed ID: 31016455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.
    Ooi GJ; Burton PR; Earnest A; Laurie C; Kemp WW; Nottle PD; McLean CA; Roberts SK; Brown WA
    Obes Surg; 2018 Feb; 28(2):427-436. PubMed ID: 28776153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
    Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
    Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into genetic variants associated with NASH-fibrosis from metabolite profiling.
    Mann JP; Pietzner M; Wittemans LB; Rolfe EL; Kerrison ND; Imamura F; Forouhi NG; Fauman E; Allison ME; Griffin JL; Koulman A; Wareham NJ; Langenberg C
    Hum Mol Genet; 2020 Dec; 29(20):3451-3463. PubMed ID: 32720691
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
    Mosca A; De Cosmi V; Parazzini F; Raponi M; Alisi A; Agostoni C; Nobili V
    J Pediatr; 2019 Aug; 211():72-77.e4. PubMed ID: 31128886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.